Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, April 01, 2021 1:00 - 5:00 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Tim Langford, PharmD, BCPS, USPHS; Robin Moody, MPH; Caryn Mickelson, PharmD.

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD, Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW.

Audience: Amber Mayzak, Pharmayclics; Andrea Willcuts, Takeda; Becky Gonzales, ViiV Healthcare; BingBing Liang, CareOregon; **Boman Irani, Rhythm Pharmaceuticals*;** Brad Brekke, Rhythm Pharmaceuticals; Brandie Ferger, Advanced Health CCO; Chi Kohlhoff, Viela Bio; Corrine Anway, OSU; **Dale Edberg, Horizon Therapeutics*;** Dave Riepe, Merck; Dennis Schaffner, Sanofi Genzyme; Donald Nopper; Apellis Pharma; Erick Nash, Covis Pharma; Janeen McBride; **Jenny Todenhagen, Genentech*;** Jeremy Strand; Alexion; Jim Graves, BMS; Kapeka Kast, PCYC; Katie Scheelar, EOCCO/Moda Health; Keely Larson, Bayer; Laura Jeffcoat, Abbvie; Maggie Murphy, Teva Pharmaceuticals; Matt Worthy, OHSU, Matthew Wright, Artia Solutions; Timothy McFerron, Alkermes; Melissa Snider, Gilead; Michael Foster, BMS; Mike Nicholson; Paul Thompson, Alkermes; Pauline Whelan; **Raffaella Colzani, MD, Sanofi Genzyme*; Shannon Zandy, Alexion Pharmaceuticals*;** Tiffany Jones, PacificSource; Tracey Harrah, AVEO Oncology; Lori McDermott, Supernus; Norm Navarro, Providence; **Amy Yang, MD, OHSU*.**

(*) Provided verbal testimony

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Written testimony: Posted to OSU Website

I. CALL TO ORDER

A. The meeting was called to order at approximately 1:06 pm. Introductions were made by Committee members and staff
B. Conflict of Interest Declaration
C. Approval of February 2021 minutes presented by Mr. Citron
ACTION: Motion to approve, 2nd, all in favor
D. Department and legislative updates provided by Dee Weston

II. CONSENT AGENDA TOPICS

A. Oncology Prior Authorization Update
ACTION: Motion to approve, 2nd, all in favor

III. DUR NEW BUSINESS

A. **Opioid Class Literature Scan:** Andrew Gibler, PharmD
Policy Evaluation: Sarah Servid, PharmD
OHA Minimum Standard: Dee Weston
Recommendations:
- Update current policy with newly approved drug products
- Modify high-risk opioid RetroDUR program criteria to include patients who may be paying cash for chronic opioid prescriptions and patients with a diagnosis of substance abuse or history of overdose
-Notify providers about risk mitigation strategies and opportunities to improve care
ACTION: The Committee recommended adding an assessment for OUD in the renewal criteria for both short-acting and long-acting PA criteria
Motion to approve, 2nd, all in favor, one abstained

B. **Antipsychotics in Children Drug Effectiveness Review Project (DERP) Summary:** Sara Fletcher, PharmD
Mental Health Polypharmacy Drug Use Evaluation: Sarah Servid, PharmD
Recommendations:
- No PDL changes recommended based on the clinical evidence
- Evaluate costs in executive session

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

- Review profiles of patients with the following high-risk categories to identify opportunities for therapy optimization or de-prescribing: long-term use multiple mental health drugs; patients with possible contraindications to therapy; and very young children

ACTION:
The Committee requested staff bring back proposed safety-edit criteria to ensure appropriate use of antipsychotics for members less than five years old when initiating therapy with an antipsychotic and to require psychiatric/specialty consultation. The Committee also recommended identifying provider education opportunities to address off-label use of antipsychotics in kids and pursue strategies to notify prescribers
Motion to approve, 2nd, all in favor

IV. PREFERRED DRUG LIST NEW BUSINESS

A. **Imcivree™ (setmelanotide) Abbreviated Drug Review (ADR):** Sara Fletcher**,** PharmD
State Plan Overview of Excluded Drugs: Dee Weston, JD
Recommendation:
- Continue to designate setmelanotide as not covered per Oregon Medicaid State Plan
Public Comment: Boman Irani, Rhythm Pharmaceuticals
ACTION: Motion to approve, 2nd, all in favor

B. **Lumizyme® (alglucosidase alfa) New Drug Evaluation (NDE):** David Engen, PharmD
Recommendations:
- Add alglucosidase alfa to the lysosomal storage disorders PDL class and designate as non-preferred
- Implement proposed alglucosidase alfa PA criteria to ensure medically appropriate use
Public Comment: Raffaella Colzani, MD, Sanofi Genzyme; Amy Yang, MD, OHSU
ACTION: Motion to approve, 2nd, all in favor

C. **Statins: Class Update:** Megan Herink, PharmD
Recommendations:
- Continue to maintain preferred low-, moderate- and high-intensity statins
- Combine high-potency and low-medium potency PDL classes into one PDL statin class
- Evaluate costs in executive session
ACTION: Motion to approve, 2nd, all in favor

D. **Neuromyelitis Optica Spectrum Disorder (NMOSD) Class Review:**
Deanna Moretz, PharmD
Recommendations:
- Add the "Biologics for Rare Diseases" class to the PDL and include inebilizumab and satralizumab

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

- Implement proposed PA criteria for each biologic agent
- Evaluate costs in executive session

Public Comment: Dale Edberg, PhD, Horizon Therapeutics; Jenny Todenhagen, Genentech

ACTION: Motion to approve, 2nd, all in favor

E. **Monoclonal Antibody C5 Inhibitors Class Review:** Deanna Moretz, PharmD
Recommendation:
- Add eculizumab and ravulizumab to the "Biologics for Rare Diseases" PDL class
- Implement proposed PA criteria for each biologic agent
- Evaluate costs in executive session

Public Comment: Shannon Zandy, Alexion Pharmaceuticals

ACTION: The Committee recommended adding age to the PA criteria for ravulizumab and to clarify that vaccination for meningitis should be given according to CDC guidance

Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Caryn Mickelson, PharmD; Robin Moody, MPH

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Megan Herink, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. **Second Generation Antipsychotics:**
Recommendation: No changes to the PDL are recommended

B. **Biologics for Rare Diseases: NMOSD treatments and C5 Inhibitors:**
Recommendation: Make eculizumab non-preferred; Make ravulizumab, satralizumab, and inebilizumab preferred

C. **Statins Class update**:
Recommendation: Make rosuvastatin tablets preferred
ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN